Loading
A phase 2 trial of nab-paclitaxel, rivoceranib (apatinib) and bevacizumab in triple-negative breast cancer, run by The First Affiliated Hospital of Bengbu Medical University, now recruiting.
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC is a phase 2, randomised interventional study registered as NCT05192798 by The First Affiliated Hospital of Bengbu Medical University, with a registry enrolment figure of 128 participants, started 2022-01-14 and due to reach its primary completion in 2027-09-10. Interventions recorded: Albumin-Bound Paclitaxel; Apatinib Mesylate; Bevacizumab. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with recurrent or metastatic triple negative breast cancer confirmed by histopathology and imaging;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Rivoceranib (apatinib), Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.